WT1 and hematologic disorder: Investigators at Memorial Sloan Kettering Cancer Centre, New York, have pioneered the use of in vitro expanded T cells specific for peptide epitopes of the Wilms Tumour 1 (WT-1) protein in patients with WT-1+ hematologic malignancies [11].